Clinical trial
Letrozole Versus Observation in Patients With Newly Diagnosed Uterine…
NCT00414076 · M.D. Anderson Cancer Center, Other · Terminated
Key facts
| NCT number | NCT00414076 |
|---|---|
| Title | Letrozole Versus Observation in Patients With Newly Diagnosed Uterine Leiomyosarcoma |
| Official title | A Randomized Phase II Study of Letrozole Versus Observation in Patients With Newly Diagnosed Uterine Leiomyosarcoma |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | Novartis Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leiomyosarcoma, Uterine Neoplasm |
| Intervention type | Drug |
| Interventions | Letrozole |
| Enrollment | 9 |
| Start date | Dec 19, 2006 |
| Primary completion | Jul 13, 2017 |
| Completion | Jul 13, 2017 |
| First posted | Dec 21, 2006 |
| Last update posted | Nov 20, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: